93 results on '"Galsky, M.D."'
Search Results
2. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
3. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
4. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
5. Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design
6. 1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C.
7. LBA5 A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)
8. 1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
9. 652P BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
10. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
11. Docetaxel-based combination therapy for castration-resistant prostate cancer
12. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
13. 2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
14. LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial
15. CO68 Simulated mOS of Gemcitabine+Carboplatin ± Maintenance Avelumab Therapy or Enfortumab Vedotin + Pembrolizumab in First-Line Treatment of LA/mUC in Patients Ineligible for Cisplatin Using Disease Modeling
16. CO24 Simulating the Impact of First-Line Treatment Choice on Survival Among Patients with Locally Advanced/Metastatic Urothelial Carcinoma Considered Cisplatin Ineligible
17. PP01.50 EMERGE-201: Phase 2 Basket Study of Lurbinectedin Monotherapy in Advanced or Metastatic Solid Tumors
18. P144 - Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase 3 CheckMate 274 trial
19. 1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)
20. 1735O PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC)
21. 1737MO Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial
22. 1274P Performance status (PS) and end-of-life (EOL) care in patients (pts) with metastatic prostate cancer (mPC) treated with androgen receptor targeted (ART) therapy
23. A0904 - Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma and the potential impact of informative censoring
24. P141 - Perioperative pembrolizumab or pembrolizumab + enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer: Phase 3 KEYNOTE-905/EV-303 study
25. SC206 - The obesity paradox in metastatic castration resistant prostate cancer
26. 699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
27. 708P PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC)
28. 704P Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA
29. 658MO Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)
30. PCN118 Estimated Prevalence of Treated Locally Advanced or Metastatic Urothelial Carcinoma in Canada Using Simulation Modeling
31. Does androgen deprivation therapy protect against severe complications from COVID-19?
32. SC298 - Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: results from the national cancer database
33. SC242 - Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial
34. SC241 - Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data
35. SC56 - The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials
36. LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)
37. 798TiP Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
38. 746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
39. 697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
40. 698O Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
41. 530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
42. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
43. O1 - Activity of the FGFR1–3 inhibitor infigratinib in patients with upper tract urothelial carcinoma and urothelial carcinoma of the bladder: Latest efficacy findings and comprehensive genomic profiling/cell-free DNA data
44. 940P - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
45. 451PD - Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours
46. 607 - Attributable fraction for the risk of death in patients with clinically localized muscle-invasive bladder cancer
47. 1241TiP - JAVELIN PARP medley: A phase Ib/II study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors
48. 902P - Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)
49. 370TiP - A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer
50. 921TiP - A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.